Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer

NCT02595138 is registered in ClinicalTrials.gov with Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT02595138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02595138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer
Lead sponsor
Chinese Academy of Medical Sciences
Phase
Phase 3
Overall status
Unknown status
Start date
October 31, 2015
Completion date
December 31, 2023
Enrollment
430 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer